AI assistant
Summit Therapeutics Inc. — Director's Dealing 2024
Sep 13, 2024
30436_dirs_2024-09-13_aa1fea10-cfc7-42ae-a4c9-bfe5c7e21b22.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2024-09-11
Reporting Person: Huber Jeff (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-09-11 | Common Stock | A | 44052 | $22.70 | Acquired | 44052 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 6000 | Indirect |
Footnotes
F1: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of September 11, 2024, pursuant to which the Issuer agreed to sell shares of common stock to Caspian Capital LLC ('Caspian Capital') at a purchase price of $22.70 per share. The transaction closed on September 13, 2024.
F2: The Reporting Person is a manager and member of Caspian Capital.
F3: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.